1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

Serotonin a la carte: Supplementation with the serotonin precursor 5-hydroxytryptophan (2006)

Serotonin a la carte: Supplementation with the serotonin precursor 5-hydroxytryptophan (2006)

  1. Anonymous
    Pharmacol Ther. (http://javascript<b></b>:AL_get(this, 'jour', 'Pharmacol Ther.');) 2006 Mar;109(3):325-38

    Turner EH (http://www.drugs-forum.com/pubmed?t....Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), Loftis JM (http://www.drugs-forum.com/pubmed?t....Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), Blackwell AD (http://www.drugs-forum.com/pubmed?t....Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract).

    This paper reviews the preclinical and clinical evidence regarding the use of the dietary supplement 5-hydroxytryptophan (5-HTP) for the
    treatment of depression. In the absence of supplementation with exogenous 5-HTP, the amount of endogenous 5-HTP available for serotonin synthesis depends on the availability of tryptophan and on the activity of various enzymes, especially tryptophan hydroxylase, indoleamine 2,3-dioxygenase, and tryptophan 2,3-dioxygenase (TDO). Factors affecting each of these are reviewed. The amount of 5-HTP reaching the central nervous system (CNS) is affected by the extent to which 5-HTP is converted to serotonin in the periphery. This conversion is controlled by the enzyme amino acid decarboxylase, which, in the periphery, can be blocked by peripheral decarboxylase inhibitors (PDIs) such as carbidopa. Preclinical and clinical evidence for the efficacy of 5-HTP for depression is reviewed, with emphasis on double-blind,
    placebo-controlled (DB-PC) trials. Safety issues with 5-HTP are also reviewed, with emphasis on eosinophilia myalgia syndrome (EMS) and
    serotonin syndrome.
Tags: